Bone mineral density changes among young, healthy African women receiving oral tenofovir for HIV preexposure prophylaxis

Journal of Acquired Immune Deficiency Syndromes

Volumn 71, Issue 3, 2016, Pages 287-294

  Mirembe, Brenda G ^a   Kelly, Clifton W ^b   Mgodi, Nyaradzo ^c   Greenspan, Susan ^d   Dai, James Y ^b   Mayo, Ashley ^e   Piper, Jeanna ^f   Akello, Carolyne A ^a   Kiweewa, Flavia M ^a   Magure, Tsitsi ^c   Nakabiito, Clemensia ^a   Marrazzo, Jeanne M ^g   Chirenje, Z Mike ^c   Riddler, Sharon A ^d  

^a MAKERERE UNIVERSITY   (Uganda)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e FAMILY HEALTH INTERNATIONAL   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

Author keywords

African women; Bone density; HIV prevention; Preexposure prophylaxis; Tenofovir

Indexed keywords

CALCIUM; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MEDROXYPROGESTERONE ACETATE; PLACEBO; TENOFOVIR DISOPROXIL; VITAMIN D; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ADULT; ARTICLE; BODY MASS; BONE DENSITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FRACTURE; GROUPS BY AGE; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; LIMIT OF DETECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; PHYSICAL ACTIVITY; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; UGANDA; VITAMIN SUPPLEMENTATION; YOUNG ADULT; ZIMBABWE; ADOLESCENT; DRUG EFFECTS; HIV INFECTIONS;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BONE DENSITY; FEMALE; HIV INFECTIONS; HUMANS; PRE-EXPOSURE PROPHYLAXIS; TENOFOVIR; UGANDA; YOUNG ADULT; ZIMBABWE;

EID: 84959077987     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000858     Document Type: Article

References (29)

1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423-434.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367: 399-410.
3. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet. 2013;381:2083-2090.
5. Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofoviremtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010;51:963-972.
6. Cassetti I, Madruga JVR, Suleiman JMA, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials. 2007;8:164-172.
7. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
8. McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavirlamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791-1801.
9. Bedimo RJ, Drechsler H, Jain M, et al. The RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. PLoS One. 2014;9(8):e106221.
10. Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825-831.
11. Koenig KF, Kalbermatter S, Menter T, et al. Recurrent bone fractures due to tenofovir-induced renal phosphate wasting. Scand J Infect Dis. 2014; 46:221-224.
12. Perrot S, Aslangul E, Szwebel T, et al. Bone pain due to fractures revealing osteomalacia related to tenofovir-induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol. 2009;15:72-74.
13. Woodward C, Hall A, Williams I, et al. Tenofovir-associated renal and bone toxicity. HIV Med. 2009;10:482-487.
14. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41.
15. Grigsby IF, Pham L, Mansky LM, et al. Tenofovir treatment of primary osteoblasts alters gene expression profiles: implications for bone mineral density loss. Biochem Biophys Res Commun. 2010;394:48-53.
16. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200:1746-1754.
17. Kasonde M, Niska RW, Rose C, et al. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One. 2014;9:e90111.
18. Liu AY, Vittinghoff E, Sellmeyer DE, et al. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One. 2011;6:e23688.
19. Mulligan K, Glidden DV, Anderson PL, et al. Effects of emtricitabine/tenofovir on bone mineral density in HIV-negative persons in a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2015;15:572-580.
20. Karlsson C, Obrant K, Karlsson M. Pregnancy and lactation confer reversible bone loss in humans. Osteoporos Int. 2001;12:828-834.
21. Mgodi NM, Kelly C, Gati B, et al. Factors associated with bone mineral density in healthy African women. Arch Osteoporos. 2015;10:1-10.
22. Gbolade B, Ellis S, Murby B, et al. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. 1998;105:790-794.
23. Gai L, Zhang J, Zhang H, et al. The effect of depot medroxyprogesterone acetate (DMPA) on bone mineral density (BMD) and evaluating changes in BMD after discontinuation of DMPA in Chinese women of reproductive age. Contraception. 2011;83:218-222.
24. Petitti D, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol. 2000;95:736-744.
25. Negredo E, Domingo P, Pérez-Álvarez N, et al. Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study). J Antimicrob Chemother. 2014;69:3368-3371.
26. Lockhart SM, Drevets DA. Reversible bone lesions induced by tenofovir disoproxil fumarate. AIDS. 2014;28:450-451.
27. Bianco C, Rossetti B, Gagliardini R, et al. Bone mineral density improvement after 48 weeks of switch to maraviroc+ darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. J Int AIDS Soc. 2014;17(4 suppl 3):19816.
28. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372:509-518.
29. Booth ML, Ainsworth BE, Pratt M, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35:1381-1395.